Enanta Q4 net loss $0.87/sh, revenue $15.1M; cash $188.9M; RSV data positive, STAT6 candidate selected

ENANTA PHARMACEUTICALS INC

2025-FY EPS reported -$3.84 vs consensus -$0.82 ▼ miss (-366.2%)

Net loss $18.7M ($0.87 loss per share) vs $28.8M loss ($1.36/sh) in Q4 2024.
Total revenue $15.1M from MAVYRET royalties; FY 2025 revenue $65.3M vs $67.6M prior year.
Ending cash $188.9M; plus $74.8M gross from Oct 2025 offering; runway into FY2029.
Zelicapavir Phase 2b in high-risk RSV adults met secondary endpoints; 2.2-day symptom resolution improvement.
Nominated EPS-3903 (STAT6 inhibitor) with >90% pSTAT6 suppression; IND target H2 2026; EDP-978 IND Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.